Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 31:7:480.
doi: 10.3389/fmed.2020.00480. eCollection 2020.

Treatment Options for COVID-19: A Review

Mukarram Jamat Ali  1 , Muhammad Hanif  2 , Muhammad Adnan Haider  3 , Muhammad Umer Ahmed  4 , Fnu Sundas  2 , Arham Hirani  4 , Izhan Ali Khan  5 , Khurram Anis  6 , Amin H Karim  7
Affiliations
Review

Treatment Options for COVID-19: A Review

Mukarram Jamat Ali et al. Front Med (Lausanne). .

Abstract

Background: The recent COVID-19 pandemic sweeping the globe has caused great concern worldwide. Due to the limited evidence available on the dynamics of the virus and effective treatment options available, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a huge impact in terms of morbidity and mortality. The economic impact is still to be assessed. Aims: The purpose of this article is to review the evidence for the multiple treatment options available, to consider the future of this global pandemic, and to identify some potential options that could revolutionize the treatment of COVID-19. Moreover, this article underscores the sheer importance of repurposing some of the available antiviral and antimicrobial agents that have long been in use so as to have an effective and expeditious response to this widespread pandemic and the need to conduct a multicenter global randomized controlled trial to find an effective single antiviral agent or a cocktail of available antimicrobial agents. Method: We thoroughly searched and reviewed various case reports, retrospective analyses, and in vitro studies published in PubMed, EMBASE, and Google Scholar regarding the treatment options used for SARS-CoV, MERS-CoV, and SARS-CoV-2 since its outbreak in an attempt to highlight treatments with the most promising results. Conclusion: We are currently facing one of the worst pandemics in history. Although SARS-CoV-2 is associated with a lower mortality rate than are SARS-CoV and MERS-CoV, its higher infectivity is making it a far more serious threat. Unfortunately, no vaccine against SARS-CoV-2 or effective drug regimen for COVID-19 currently exists. Drug repurposing of available antiviral agents may provide a respite; moreover, a cocktail of antiviral agents may be helpful in treating this disease. Here, we have highlighted a few available antimicrobial agents that could be very effective in treating COVID-19; indeed, a number of trials are underway to detect and confirm the efficacy of these agents.

Keywords: COVID-19; SARS-CoV-2; chloroquine/hydroxychloroquine; immunoglobulin; ivermectin; remdesivir; tocilizumab.

PubMed Disclaimer

References

    1. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. (2020) 12:254. 10.3390/v12030254 - DOI - PMC - PubMed
    1. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. (2020) 55:105960. 10.1016/j.ijantimicag.2020.105960 - DOI - PMC - PubMed
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020) 9:ciaa237. 10.1093/cid/ciaa237. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Weston S, Haupt R, Logue J, Matthews K, Frieman M. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. BioRxiv. (2020). 10.1101/2020.03.25.008482 - DOI - PMC - PubMed
    1. Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, et al. . Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. (2015) 96:3484–92. 10.1099/jgv.0.000309 - DOI - PMC - PubMed